Abstract
Renal cell carcinomas (RCCs) are the seventh most common cancer in men and tenth most common cancer in women. RCC is a complex entity, and the pathologic classification of renal carcinomas has been constantly evolving since the basic classification in 1986 by Thoenes et al., although the term typing/classification was first used by Murhpy and Mostofi in 1965. Due to the explosion in recent years of molecular advances, the classification of RCCs has undergone many changes, with many new molecularly defined entities, as well as newer morphologically defined entities with prognostic implications, and redefining and renaming of previously well-known entities. Due to the vast changes in the complexities of RCCs, this chapter has tried to focus on the basic WHO (5th edition classification, 2022) classification of RCCs, with emphasis on the changes and newer entities, pathologic factors that affect prognosis in RCCs, and finally, the most important prognostic factor, the pathologic tumor stage.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Moch H, et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours. Eur Urol. 2022;82(5):458–68.
Agnihotri S, et al. Renal cell carcinoma in India demonstrates early age of onset & a late stage of presentation. Indian J Med Res. 2014;140(5):624–9.
Kabaria R, et al. Renal cell carcinoma: links and risks. Int J Nephrol Renovasc Dis. 2016;9:45–52.
Chow WH, et al. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7(5):245–57.
Neumann HP, et al. Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma. J Urol. 1998;160:1248–54.
Przybycin CG, et al. Hereditary syndromes with associated renal neoplasia: a practical guide to histologic recognition in renal tumor resection specimen. Adv Anat Pathol. 2013;20(4):245–63.
Farley MN, et al. A novel Germline mutation in BAP-1 predisposes to familial clear-cell renal cell carcinoma. Mol Cancer Res. 2013;11(9):1061–71.
Glasker S, et al. Von Hippel-Lindau disease: current challenges and future prospects. Onco Targets Ther. 2020;13:5669–90.
Kennedy JM, et al. Clinical and morphologic review of 60 hereditary renal tumors from 30 hereditary renal cell carcinoma syndrome patients: lessons from a comtemporary single institution series. Med Oncol. 2019;36(9):74. https://doi.org/10.1007/s12032-019-1297-6.
Toro JR, et al. Birt-Hogg-Dube syndrome: a novel marker of kidney neoplasia. Arch Dermatol. 1999;135(10):1195–202.
Schmidt L, et al. Molecular genetics and clinical features of Birt-Hogg-Dube syndrome. Nat Genet. 1997;16(1):68–73.
Menko FH, et al. Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Familial Cancer. 2014;13(4):637–44.
Abdel-Rahman MH, et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma and other cancers. J Med Genet. 2011;48(12):856–9.
Yang Y, et al. Characterization of genetically defined sporadic and hereditary type 1papillary renal cell carcinoma cell lines. Genes Chromosomes Cancer. 2021;60(6):434–46.
WHO Classification of Tumours Editorial Board. Urinary and male genital tumours, vol. 8. 5th ed. Lyon: International Agency for Research on Cancer; 2022.
Mitchell TJ, et al. Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal. Cell. 2018;173(3):611–623.e17.
Pitra T, et al. Chromosomal numerical aberration pattern in papillary renal cell carcinoma: review article. Ann Diagn Pathol. 2019;40:189–99.
Garje R, et al. Comprehensive review of chromophobe renal cell carcinoma. Crit Rev Oncol Hematol. 2021;160:103287.
Williamson SR. Clear cell papillary renal cell carcinoma: an update after 15 years. Pathology. 2021;53(1):109–19.
Trpkov K, et al. Eosinophilic, solid, and cystic renal cell carcinoma. Am J Surg Pathol. 2016;40(1):60–71.
Sharma R, et al. Eosinophilic solid and cystic renal cell carcinoma: from unclassified to classified, a case report. Turk Patoloji Derg. 2022;38(1):60–5.
Nathany S, Monappa V. Mucinous tubular and spindle cell carcinoma: a review of histopathology and clinical and prognostic implications. Arch Pathol Lab Med. 2020;144(1):115–8.
Seo AN, et al. Clinicopathologic and molecular pathology of collecting duct carcinoma and related renal cell carcinomas. Adv Anat Pathol. 2017;24(2):65–77.
Muller M, et al. Pattern multiplicity and fumarate hydratase (FH)/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tum. Mod Pathol. 2018;31(6):974–83.
Argani P. Translocation carcinomas of the kidney. Genes Chromosom Cancer. 2022;61(5):219–27.
Kuroda N, et al. Review of succinate dehydrogenase-deficient renal cell carcinoma with focus on clinical and pathobiological aspects. Pol J Pathol. 2016;1:3–7.
Cheng JX, et al. Renal medullar carcinoma:rhabdoid features and the absence of INI1 expression as markers of aggressive behaviour. Mod Pathol. 2008;21(6):647–52.
Trpkov K, et al. New developments in existing WHO entities and evolving molecular concepts: the genitourinary pathology society (GUPS) update on renal neoplasia. Mod Pathol. 2021;34(7):1392–424.
Truong LD, Shen SS. Immunohistochemical diagnosis of renal neoplasms. Arch Pathol Lab Med. 2011;135(1):92–109.
Akgul M, Williamson SR. Immunohistochemistry for the diagnosis of renal epithelial neoplasms. Semin Diagn Pathol. 2022;39(1):1–16.
Delahunt B, et al. Grading of renal cell carcinoma. Histopathology. 2019;74(1):4–17.
Dagher J, et al. Percentage grade 4 tumor predicts outcome for clear cell renal cell carcinoma. Pathology. 2019;51(4):349–52.
Samaratunga H, et al. Granular necrosis: a distinctive form of cell death in malignant tumors. Pathology. 2020;52(5):507–14.
Amin MB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Rao, M., Thirunavukkarasu, B. (2023). Pathology and Staging. In: Singh, P., Nayak, B., Panaiyadiyan, S. (eds) A Guide to Management of Urological Cancers. Springer, Singapore. https://doi.org/10.1007/978-981-99-2341-0_2
Download citation
DOI: https://doi.org/10.1007/978-981-99-2341-0_2
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-99-2340-3
Online ISBN: 978-981-99-2341-0
eBook Packages: MedicineMedicine (R0)